Table 1.
Baseline Characteristics of patients between radial and femoral access groups.
| Radial N = 4046 (74.6%) | Femoral N = 1374 (25.4%) | P Value | |
|---|---|---|---|
| Age | 57.10 (±9.96) | 58.36 (±9.69) | <0.001 |
| BMI | 25.64 (±3.73) | 25.5 (±3.73) | 0.319 |
| Male | 84.1% | 81.4% | 0.023 |
| Dyslipidemia | 36.5% | 35.2% | 0.417 |
| Hypertension | 69.6% | 71.3% | 0.261 |
| Diabetes | 37.9% | 38.7% | 0.650 |
| MI History | 33.2% | 35.1% | 0.211 |
| HF History | 20.3% | 25.3% | <0.001 |
| CVD History | 2.5% | 2.8% | 0.561 |
| PVD History | 0.4% | 0.6% | 0.492 |
| CKD History | 9.3% | 11.9% | 0.007 |
| On Dialysis | 0.6% | 0.9% | 0.231 |
| 2nd & 3rd deg AVB | 0.8% | 2.5% | <0.001 |
| RBBB | 1.4% | 1.6% | 0.651 |
| AF | 1.3% | 1.2% | 0.731 |
| LBBB | 0.7% | 0.5% | 0.532 |
| Family History of Premature CAD | 12% | 10.7% | 0.246 |
| Documented Significant CAD | 46.6% | 61.2% | <0.001 |
| Previous PCI | 25.8% | 37.5% | <0.001 |
| Previous CABG | 1.1% | 4.6% | <0.001 |
| New-onset Angina | 21.4% | 14.9% | <0.001 |
| Medications at Discharge | |||
| Aspirin | 95.7% | 94.0% | 0.01 |
| Clopidogrel | 84.6% | 86.8% | 0.056 |
| Ticlopidine | 0.1% | 0% | 0.578 |
| Warfarin | 1.1% | 1.4% | 0.459 |
| Prasugrel | 0.3% | 0% | 0.076 |
| Ticagrelor | 11.6% | 8.4% | 0.001 |
| NOAC | 0% | 0.1% | 0.251 |
| Statin | 93.4% | 91.4% | 0.019 |
| Beta Blocker | 81.6% | 81.6% | 1.000 |
| ACE Inhibitor | 52.9% | 46.2% | <0.001 |
| ARB | 26% | 32.5% | <0.001 |
Description: ACE = Angiotensin Converting Enzyme; AF = Atrial Fibrillation; ARB = Angiotensin Receptor Blocker; AVB = Atrioventricular Block; CAD = Coronary Artery Disease; CKD = Chronic Kidney Disease; CVD = Cerebrovascular Disease; HF = Heart Failure; LBBB = Left-bundle Branch Block; PCI = Percutaneous Coronary Intervention; PVD = Peripheral Vascular Disease; NOAC = Non-vitamin K Antagonist Oral Anticoagulant; RBBB = Right-bundle Branch Block.